about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaK-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysisOncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilizationExpression of S100P and its novel binding partner S100PBPR in early pancreatic cancerPlectin-1 as a novel biomarker for pancreatic cancer.Emerging concepts in pancreatic cancer medicine: targeting the tumor stromaReview of screening for pancreatic cancer in high risk individualsStructure, evolution, and biology of the MUC4 mucinNew-onset diabetes: a potential clue to the early diagnosis of pancreatic cancerK-ras and Dpc4 mutations in chronic pancreatitis: case series5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissueWhat is the origin of pancreatic adenocarcinoma?Targeting inflammation in pancreatic cancer: Clinical translationKey players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cellsDiet and Pancreatic Cancer PreventionMolecular detection of pancreatic neoplasia: Current status and future promiseMolecular Targeted Intervention for Pancreatic CancerCytology Specimen Management, Triage and Standardized Reporting of Fine Needle Aspiration Biopsies of the PancreasPancreatic adenocarcinoma pathology: changing "landscape"Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesTargeting p110gamma in gastrointestinal cancers: attack on multiple frontsMolecular landscape of pancreatic cancer: implications for current clinical trialsVaccines for pancreatic cancerImpacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancerEvolution and dynamics of pancreatic cancer progressionLinks between mutant p53 and genomic instabilityEndoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancerExploiting inflammation for therapeutic gain in pancreatic cancerClonal dynamics following p53 loss of heterozygosity in Kras-driven cancers.Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancerDPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear StructureEvaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancerBLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferationDNA damage response genes and the development of cancer metastasisMechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cellsRas history: The saga continues.Age-specific incidence of cancer: Phases, transitions, and biological implicationsNew markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.
P2860
Q21129230-63501F93-FAE9-4845-BB8D-E8B66117BABFQ21284688-2B474C6D-BB3D-46D2-B8CC-50DE6DB7400CQ24316003-0BFE6295-B046-4EB7-BB1A-840DE3E8A694Q24337345-2BED6E67-E977-4A03-936A-C0710D33C617Q24615622-85D04785-70D8-47F7-8021-AC500C744AC3Q24627664-F3D7C0B3-A6E9-4E32-9AAD-2A39E56E30A1Q24630198-F8B4F024-A73A-4AAE-9F25-9C7DF43BFCE6Q24630985-3A75CB3E-4471-4A67-BB99-F3AD5E8E0C14Q24656132-E1C4499E-CEE4-448A-8A71-D5F89EB9F67AQ24676729-99E6112A-D2CF-484B-8553-09B2C9B49989Q24685466-37A5065A-E0BC-4688-8364-1F78BE5C315FQ24805751-C358F8DC-B94D-412E-9908-7DF1D85732E8Q26751686-7E2DF41B-4C88-41E9-9DC0-BBE309902BD2Q26766065-DB2046E6-BD9A-452A-9BCD-297B449514B8Q26776524-828F8AFF-B414-4CE0-88F7-A594C81BD6C2Q26777379-61AF9A2C-4112-4A37-A0BB-3BF6713C8634Q26798453-F8286BDB-27B8-41FB-A729-730703906166Q26799060-6AC761D7-E7A6-4D84-A2E9-691EF3C3D0BCQ26799446-F9B2F2CC-3C08-4B86-A6E7-4FEBBD6E1EF6Q26799714-1D9371FF-33A4-4BAA-9275-3AF7946A65F7Q26823575-B676F6E4-9471-4CFA-BAC5-35CE3C197E38Q26824528-357F230B-5A22-4CC5-82AC-51EB839F32E4Q26825850-E8F4501E-8417-4056-9D5E-B4EDC6CFC932Q26830681-C0672A13-7C48-4666-9C22-15212170BC4FQ26849671-49E38400-19FB-47D7-AE89-F1B336542D4CQ26864033-3A97C9C1-3F7E-43D1-BF81-5E49D72205E3Q27010209-5598B571-98BD-4BFF-9CFA-33B0DDE3A053Q27027661-A049D1D9-3BEB-4ECD-AD45-0BA59F91ADF2Q27329427-EE1AE6B9-9592-4E74-A3C4-ED3B49B72885Q27334957-C1F6C9DB-F3B5-4F5D-82E1-D2033F8E3624Q27851466-0596A8E4-45D0-4529-B83F-109DEFEFC72DQ28079848-D7F8AF26-0584-4DBA-B3A5-58ABFDF4E994Q28084785-3FF6F383-01DA-46D9-B5AC-DDB94EA5CF30Q28238203-60FAC6DE-1201-4B56-BA94-CCD2DF813692Q28293407-07C92135-FA46-4958-8D94-CA646DF44B2AQ28388312-66A39307-5534-4DCC-A0C4-B8F57CC521E8Q28485201-3F87516F-73DD-423B-9041-99E9415F499FQ30404024-3F5E4001-73C5-4C2B-978A-F894083F57AAQ30484186-74D867AA-2506-4220-A41A-7800DDA334C2Q30489770-441F544F-F236-4B49-91BD-4B184D584365
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Progression model for pancreatic cancer.
@ast
Progression model for pancreatic cancer.
@en
Progression model for pancreatic cancer.
@nl
type
label
Progression model for pancreatic cancer.
@ast
Progression model for pancreatic cancer.
@en
Progression model for pancreatic cancer.
@nl
prefLabel
Progression model for pancreatic cancer.
@ast
Progression model for pancreatic cancer.
@en
Progression model for pancreatic cancer.
@nl
P2093
P1476
Progression model for pancreatic cancer
@en
P2093
P304
P407
P577
2000-08-01T00:00:00Z